Similarly, inhibition of EZH2, a histone H3 Lys27 (H2K27) methyltransferase and polycomb group protein, is associated with up-regulation of ERα in breast cancer cells, suggesting that targeting of EZH2 provides an option for restoring response to tamoxifen in endocrine-resistant breast cancers [79]. The gene discussed is ESR1; the disease is breast carcinoma.